Recce Pharmaceuticals (RCE) News Today Add Compare Share Share Headlines Stock AnalysisBuy This Stock RCE Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period The past five years for Recce Pharmaceuticals (ASX:RCE) investors has not been profitableMay 26, 2025 | finance.yahoo.comRecce secures Chinese patent as it targets superbugs with new anti-infectivesMay 26, 2025 | msn.comRecce Pharmaceuticals Expands Patent Portfolio to ChinaMay 25, 2025 | tipranks.comFIL Limited Increases Stake in Recce PharmaceuticalsMay 19, 2025 | tipranks.comRecce Pharmaceuticals Director Increases ShareholdingMay 16, 2025 | tipranks.comRecce Pharmaceuticals Secures Canadian R&D RebateMay 5, 2025 | tipranks.comRecce Pharmaceuticals Extends Entitlement Offer DeadlineApril 30, 2025 | tipranks.comRecce Pharmaceuticals Updates Securities Issue TimelineApril 30, 2025 | tipranks.comBreak it Down: Recce partners with the US ArmyApril 28, 2025 | msn.comRecce Pharmaceuticals Partners with USAMRIID for Biodefense Pathogen TestingApril 27, 2025 | tipranks.comRecce Pharmaceuticals Updates Investors on Clinical Progress and FundingApril 22, 2025 | tipranks.comRecce Raises $4M from Heavybit and Open-Source Leaders to Bring Data-Native Code Review to Data-Driven Software and AI SystemsApril 22, 2025 | finance.yahoo.comRecce to expand Phase II trial for diabetic foot infectionsApril 22, 2025 | msn.comRecce adds 20 more people to trial for R327G foot gelApril 22, 2025 | msn.comRecce Pharmaceuticals Expands Phase II Trial for Diabetic Foot InfectionsApril 21, 2025 | tipranks.comRecce Pharmaceuticals Opens Entitlement Offer to Raise $10.8 MillionApril 21, 2025 | tipranks.comRecce Pharmaceuticals Raises A$5 Million Through Share PlacementApril 16, 2025 | tipranks.comRecce Pharmaceuticals Secures Funding for Advanced Clinical TrialsApril 16, 2025 | tipranks.comRecce to raise $15.8M in trial funds through placement, entitlement offerApril 10, 2025 | msn.comRecce to raise $15.8M in Placement and Entitlement Offer to fund trialsApril 10, 2025 | msn.comRecce Pharmaceuticals Announces A$5.0 million Placement & Launches A$10.8 million Entitlement Offer to ShareholdersApril 10, 2025 | finance.yahoo.comRecce raising up to $15.8m for Phase III trialsApril 9, 2025 | msn.comRecce Pharmaceuticals Launches Equity Raising InitiativeApril 9, 2025 | tipranks.comRecce Pharmaceuticals Secures A$15.8 Million for Phase III TrialsApril 9, 2025 | tipranks.comRecce Pharmaceuticals Unveils Strategic Focus on Synthetic Anti-InfectivesMarch 19, 2025 | tipranks.comBiocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trialMarch 11, 2025 | msn.comRecce Pharmaceuticals Granted Japanese Patent for RECCE® Anti-InfectivesFebruary 27, 2025 | markets.businessinsider.comRecce Pharmaceuticals secures Japanese patent in world’s third-largest pharmaceutical marketFebruary 26, 2025 | au.investing.comRecce Pharmaceuticals Secures Japan Patent for Anti-InfectivesFebruary 25, 2025 | tipranks.comRecce Pharmaceuticals receives positive Phase II results for R327G in bacterial skin infectionsFebruary 17, 2025 | au.investing.comRecce soars on phase II skin infection trial resultsFebruary 17, 2025 | msn.comRecce finds foot gel to be efficacious in Phase II clinical trialFebruary 17, 2025 | msn.comRecce Pharmaceuticals Ltd Initiates Trading Halt Ahead of Key Clinical Trial ResultsFebruary 12, 2025 | tipranks.comRecce Pharmaceuticals Advances Clinical Trials with New Approvals and Financial BoostJanuary 31, 2025 | tipranks.comRecce Pharmaceuticals Doses All Patients in Phase II Trial of RECCE® 327 Topical Gel in Acute Bacterial Skin and Skin Structure InfectionsJanuary 22, 2025 | markets.businessinsider.com'Significant' new milestone for Recce in clinical testing of skin infection gelJanuary 21, 2025 | msn.comRecce Pharmaceuticals doses all patients in phase II skin infection trialJanuary 21, 2025 | msn.comRecce Pharmaceuticals Completes Patient Dosing in Phase II Trial for Topical GelJanuary 20, 2025 | tipranks.comRoad to 2025: Recce’s calendar of clinical accomplishmentDecember 23, 2024 | msn.comRecce gets Indonesian nod for phase III trial of diabetic foot infection treatmentDecember 8, 2024 | msn.comRecce Pharmaceuticals advances global reach with Indonesia’s approval for Phase 3 Diabetic Foot Infection TrialDecember 8, 2024 | msn.comInvestors in Recce Pharmaceuticals (ASX:RCE) have seen notable returns of 68% over the past five yearsDecember 2, 2024 | uk.finance.yahoo.comRecce Pharmaceuticals Highlights Risks and Cautions InvestorsNovember 27, 2024 | tipranks.comRecce Pharmaceuticals Granted Australia Patent for RECCE® Anti-InfectivesNovember 27, 2024 | markets.businessinsider.comComplete patent protection for 2 Recce anti-infective treatmentsNovember 27, 2024 | msn.comRecce Pharmaceuticals Secures Global Patent for Anti-InfectivesNovember 26, 2024 | markets.businessinsider.comASX health stocks fighting superbugs to save livesNovember 20, 2024 | msn.comRecce scores $6.75M R&D rebateNovember 14, 2024 | msn.comRecce Pharmaceuticals Boosted by $6.75M R&D RebateNovember 14, 2024 | markets.businessinsider.comRecce Pharmaceuticals garners ethics approval for anti-infective Phase 3 clinical trial in IndonesiaNovember 11, 2024 | au.investing.com Get Recce Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter. Email Address RCE Media Mentions By Week RCE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RCE News Sentiment▼0.600.87▲Average Medical News Sentiment RCE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RCE Articles This Week▼31▲RCE Articles Average Week Get Recce Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RCE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies PureTech Health News Today Zenas Biopharma News Today Oxford Biomedica News Today Faron Pharmaceuticals Oy News Today NervGen Pharma News Today Fennec Pharmaceuticals News Today Cybin News Today Bioventix News Today 4basebio News Today Avacta Group News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ASX:RCE) was last updated on 5/31/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredAs Bitcoin supply vanishes, this Trump-aligned token could explodeBitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recce Pharmaceuticals Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Recce Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RCE Stock Free RCE Stock Alerts